Cardiometabolic Risk

Cardiometabolic Risk

Cardiometabolic risk encompasses the cluster of interrelated metabolic abnormalities that collectively increase the likelihood of cardiovascular events such as heart attack and stroke, as well as the development of type 2 diabetes. Key risk factors include central obesity, elevated triglycerides, low HDL cholesterol, hypertension, elevated fasting glucose, and insulin resistance. These factors frequently co-occur and share underlying pathophysiological mechanisms, particularly visceral adiposity-driven chronic low-grade inflammation and endothelial dysfunction.

The clinical significance of cardiometabolic risk extends beyond any single biomarker. Individuals with multiple concurrent risk factors face a multiplicative rather than additive increase in their probability of adverse outcomes. This understanding has driven the development of therapies that address the root causes of cardiometabolic disease—primarily excess adiposity—rather than treating individual risk factors in isolation. Weight loss of >10% body weight has been shown to meaningfully improve nearly all cardiometabolic parameters, including blood pressure, lipid profiles, glycemic control, and inflammatory markers.

Retatrutide’s substantial weight loss effects in Phase 2 trials translated into broad cardiometabolic improvements. The TRIUMPH-2 Phase 3 trial specifically evaluates retatrutide in individuals with obesity and cardiometabolic comorbidities, with co-primary endpoints that include both weight reduction and improvements in cardiometabolic risk markers. This trial design reflects the growing recognition that effective obesity treatment should be assessed not only by weight loss magnitude but also by its downstream impact on cardiovascular and metabolic health.